In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The superimposed myocarditis in arrhythmogenic right ventricular cardiomyopathy: the role in the course of the disease and the results of treatment

Session Poster Session 3

Speaker Olga Blagova

Congress : Heart Failure 2019

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Myocarditis
  • Session type : Poster Session
  • FP Number : P1810

Authors : Y A Lutokhina (Moscow,RU), OV Blagova (Moscow,RU), AV Nedostup (Moscow,RU), SA Alexandrova (Moscow,RU), EA Mershina (Moscow,RU), VA Zaidenov (Moscow,RU), AG Shestak (Moscow,RU), EV Zaklyazminskaya (Moscow,RU)

Y A Lutokhina1 , OV Blagova1 , AV Nedostup1 , SA Alexandrova2 , EA Mershina3 , VA Zaidenov4 , AG Shestak5 , EV Zaklyazminskaya5 , 1I.M. Sechenov First Moscow State Medical University - Moscow - Russian Federation , 2Bakoulev Center for Cardiovascular Surgery RAMS - Moscow - Russian Federation , 3Roszdrav Medical Rehabilitation Center - Moscow - Russian Federation , 4City Clinical Hospital No. 52 - Moscow - Russian Federation , 5Russian Research Center of Surgery, Petrovsky - Moscow - Russian Federation ,


Purpose: to study the role of myocarditis in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC), and to evaluate the results of its treatment.
Methods: 54 patients (38.7±14.1 y., 42.6% men) with ARVC according to Revised Task Force Criteria 2010 were evaluated (34 patients with definite, 18 - with borderline, 2 with possible diagnosis). Follow-up period 21 [6; 60] months. All patients underwent ECG, 24h-Holter monitoring, echocardiography, DNA-diagnostic, blood tests for detection of anti-heart antibodies (AHA) and DNA of viruses. Also were performed cardiac MRI (n=49), signal-averaged ECG (n=18), endomyocardial biopsy (n= 2), autopsy (n=2).
Results: myocarditis was diagnosed in 38 (70.4%) patients, 8 of whom were virus-positive (2 by myocardium, 6 by blood). Immunosuppressive therapy (IST) was conducted in 25 patients and included hydroxychloroquine (n=22, 200 mg/day), steroids (n=7, 16 [8; 24] mg/day), azathioprine (n=2, 150 mg/day). Patients with myocarditis who received and not received IST were compared. Initially, patients receiving IST had a longer term of disease, higher titers of AHA and a larger end diastolic volume of the left ventricle (LV) by MRI. Patients who received IST, had significantly lower mortality in comparison with patients with myocarditis without treatment (4.0 vs 30.8%, p=0.03). Only patients with myocarditis treated with IST demonstrated significant positive dynamics in PV?s number (11,7 [2,6; 37] vs 0,8 [0,01; 4.5] thousand/day., p<0.001); nonsustained ventricular tachycardia (VT, 57.9 vs 26.3%, p=0.034); sustained VT (SVT, 31.6 vs 0%, p=0.014); their LV ejection fraction (EF) remained stable (52.1±14.8 vs 52.4±13.5%, p=0.58). In patients with myocarditis without IST, there was a tendency to EF reduction (64,3±8,8 vs 57,2±9,4, p=0,058). Comparison of patients with isolated ARVC and ARVC plus myocarditis revealed no differences in structural and functional parameters (severity of arrhythmias, EF of both ventricles, heart chambers size, functional class of CHF, etc.), in the effectiveness of radiofrequency ablation and in the frequency of adverse outcomes. The absence of differences is regarded as the result of effective IST. However, myocarditis was significantly less common in patients with the most typical form of ARVD (SVT without significant CHF; with mutations in the PKP2 gene) than in patients with latent arrhythmic form (without SVT, with mutations in the DSG, SCN5A, FLNC genes) and with biventricular ?HF (mutations in DSP, DES genes).
Conclusion: the frequency of superimposed myocarditis in patients with ARVC exceeds 70%. Myocarditis in ARVC could be primary (including viral) or secondary (autoimmune). Regardless to etiology, myocarditis in ARVC should be actively diagnosed and treated, because patients with myocarditis not receiving IST have significantly worse effectiveness of antiarrhythmic therapy and outcomes in comparison with patients with ARVD and myocarditis, received IST.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are